Mismatch repair cancer syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:12:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mismatch repair cancer syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Dostarlimab Combined with Short Course Radiotherapy for Locally Advanced Rectal Cancer Patients with Microsatellite Instability https://clinicaltrials.eu/trial/study-of-dostarlimab-and-short-course-radiotherapy-for-patients-with-locally-advanced-rectal-cancer-with-microsatellite-instability-or-mismatch-repair-deficiency/ Wed, 29 Apr 2026 15:01:10 +0000 https://clinicaltrials.eu/trial/study-of-dostarlimab-and-short-course-radiotherapy-for-patients-with-locally-advanced-rectal-cancer-with-microsatellite-instability-or-mismatch-repair-deficiency/ This study focuses on patients with locally advanced rectal cancer that has specific genetic characteristics – microsatellite unstable or mismatch repair-deficient. These terms refer to specific changes in the cancer cells that affect how DNA repairs itself. The study evaluates a treatment approach combining dostarlimab (marketed as JEMPERLI), which is given through intravenous infusion, with a short course of radiotherapy.

The main purpose of this research is to determine how effective this combination treatment is in controlling the cancer without the need for surgery. The treatment involves receiving dostarlimab infusions along with radiation therapy. After treatment, patients will be monitored to see if their cancer completely disappears, which would allow them to avoid surgery.

During the study, patients will receive dostarlimab infusions at a dose of 500 mg for up to 6 months. The effectiveness of this approach will be evaluated over a two-year period to check if the cancer remains controlled without surgery. Doctors will monitor patients’ overall health, how well the cancer responds to treatment, and whether the cancer returns after initial response.

]]> Study on the Safety and Efficacy of CR6086 and Balstilimab for Patients with Pretreated Metastatic Colorectal and Other GI Cancers https://clinicaltrials.eu/trial/study-on-the-safety-and-efficacy-of-cr6086-and-balstilimab-for-patients-with-pretreated-metastatic-colorectal-and-other-gi-cancers/ Wed, 29 Apr 2026 15:00:49 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-efficacy-of-cr6086-and-balstilimab-for-patients-with-pretreated-metastatic-colorectal-and-other-gi-cancers/ This clinical trial is focused on studying the effects of a new treatment combination for patients with certain types of advanced cancers. The diseases being studied include metastatic colorectal cancer and other metastatic gastrointestinal cancers. These are cancers that have spread to other parts of the body and are known to be difficult to treat. The treatment being tested combines two medications: CR6086, which is an immunomodulator, and Balstilimab (also known by its code name AGEN2034), which is a type of medication called a PD-1 inhibitor. PD-1 inhibitors help the immune system recognize and attack cancer cells.

The purpose of this study is to evaluate the safety and effectiveness of this combination treatment. Participants in the study will receive both medications, with CR6086 taken as a capsule by mouth and Balstilimab given as an infusion into a vein. The study will monitor patients over a period of 24 weeks to see how well the treatment works and to check for any side effects. The goal is to determine if this combination can help control the disease in patients who have already received other treatments.

Throughout the study, doctors will assess the safety of the treatment by observing any side effects and changes in health. They will also measure how well the treatment works by looking at the disease control rate, which includes the number of patients whose cancer shrinks, disappears, or remains stable. This study aims to provide new insights into treating these challenging cancers and potentially offer a new option for patients in the future.

]]> Study on Atezolizumab and Tiragolumab for Patients with Head and Neck Cancer, Metastatic Melanoma, and Other Advanced Solid Tumors https://clinicaltrials.eu/trial/study-on-atezolizumab-and-tiragolumab-for-patients-with-head-and-neck-cancer-metastatic-melanoma-and-other-advanced-solid-tumors/ Wed, 29 Apr 2026 14:58:21 +0000 https://clinicaltrials.eu/trial/study-on-atezolizumab-and-tiragolumab-for-patients-with-head-and-neck-cancer-metastatic-melanoma-and-other-advanced-solid-tumors/ This clinical trial is focused on studying the effects of two medications, Tiragolumab and Tecentriq (also known as Atezolizumab), on various types of cancer. The diseases being studied include Head and Neck Squamous Cell Carcinoma (HNSCC), metastatic deficient mismatch repair (dMMR) or MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, and other locally advanced or metastatic solid tumors. The purpose of the study is to evaluate how well these medications work in treating these cancers.

Participants in the study will receive the medications through an infusion, which means the drugs are given directly into the bloodstream. The study will observe how the tumors respond to the treatment over a period of time. The trial is designed to see if the combination of Tiragolumab and Tecentriq can help shrink the tumors or stop them from growing. The study will also monitor the safety of the medications and any side effects that may occur.

The trial is open-label, meaning both the researchers and participants know which treatment is being administered. The study will include different groups of patients, each with specific types of cancer, to determine the effectiveness of the treatment across various conditions. The trial aims to provide valuable information on whether these medications can be beneficial for patients with these types of cancer.

]]> Study on the Effectiveness of Botensilimab and Balstilimab for Patients with Various dMMR and pMMR Tumors https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-botensilimab-and-balstilimab-for-patients-with-various-dmmr-and-pmmr-tumors/ Wed, 29 Apr 2026 14:26:25 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-botensilimab-and-balstilimab-for-patients-with-various-dmmr-and-pmmr-tumors/ This clinical trial is focused on studying various types of cancers, including but not limited to, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Endometrial Cancer, Breast Cancer, Prostate Cancer, and Sarcoma. The study aims to evaluate the effectiveness of a combination of two investigational drugs, Botensilimab and Balstilimab. Botensilimab, also known by its code name AGEN1181, is a type of protein called a monoclonal antibody that targets a specific protein on cancer cells. Balstilimab, or AGEN2034, is another monoclonal antibody that works by blocking a protein that helps cancer cells evade the immune system.

The purpose of this study is to determine how well these drugs work together in treating the cancers mentioned. Participants will receive these medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will observe the response of the tumors to this treatment, particularly looking for a significant reduction in the amount of cancerous tissue remaining after the treatment. This is known as a major pathologic response, where ideally less than 10% of the tumor remains after the treatment.

The study will also assess the safety and feasibility of using these drugs before surgery in patients with these cancers. Participants will be monitored for any side effects and the overall impact of the treatment on their health. The trial will help researchers understand if this combination of drugs can be a beneficial treatment option for patients with these types of cancers.

]]>